/images/ppid_59c68470-image-177868503576365095.webp)
/images/ppid_a911dc6a-image-177886282797047720.webp)
What is the story about?
Diagnostic chain Metropolis Healthcare Ltd on Wednesday (May 13) reported a net profit of ₹51 crore for the fourth quarter, compared with ₹22 crore in the corresponding quarter last year, marking a year-on-year increase of about 131.8%.
Revenue on a consolidated basis rose 23% year-on-year to ₹425 crore from ₹345 crore. EBITDA increased 73.4% year-on-year to ₹108 crore from ₹62.3 crore, while margins improved to 25.4% from 18% in the same period last year.
The company reported a 11% year-on-year growth in patient volumes, while test volumes increased 14% year-on-year, supported by demand momentum, deeper market penetration and stronger clinician engagement.
ALSO READ | Metropolis Health shares rise nearly 5% post positive Q3 business update
B2C revenues rose 20% year-on-year, driven by higher adoption of preventive and specialised testing, stronger digital engagement and hyperlocal marketing initiatives. B2B revenues increased 28% year-on-year, supported by client retention, hospital outsourcing opportunities, stronger partner relationships and improved service reliability.
The company’s TruHealth portfolio grew 24% year-on-year, while the specialty portfolio increased 31% year-on-year, reflecting higher consumer preference for preventive healthcare and advanced diagnostics.
Revenue per patient (RPP) improved 11% year-on-year, while revenue per test (RPT) increased 8% year-on-year, supported by a favourable mix and higher contribution from specialised testing.
ALSO READ | Metropolis Healthcare Q2 net profit rises 13% on TruHealth, specialty portfolio growth
The company said robust demand and operational efficiencies drove margin expansion and profitability improvement. It also crossed the milestone of 5,000+ centres, strengthening accessibility and market presence across India.
The company has declared a second interim dividend of ₹1 per equity share of face value ₹2 for the financial year 2025-26. It has fixed Tuesday, May 19, 2026, as the record date for determining shareholder eligibility for the interim dividend. The dividend will be paid within 30 days of its declaration.
Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Ltd, said, "The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. At Metropolis, our focus on scientific excellence, strong doctor relationships and advanced diagnostics positions us well in this evolving healthcare landscape,” adding, “In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India.”
ALSO READ | Metropolis Healthcare targets 13-15% revenue growth in FY26 on preventive and specialty push
Shares of Metropolis Healthcare Ltd ended at ₹550, up by ₹2, or 0.36%, on the BSE today, May 13.
Revenue on a consolidated basis rose 23% year-on-year to ₹425 crore from ₹345 crore. EBITDA increased 73.4% year-on-year to ₹108 crore from ₹62.3 crore, while margins improved to 25.4% from 18% in the same period last year.
The company reported a 11% year-on-year growth in patient volumes, while test volumes increased 14% year-on-year, supported by demand momentum, deeper market penetration and stronger clinician engagement.
ALSO READ | Metropolis Health shares rise nearly 5% post positive Q3 business update
B2C revenues rose 20% year-on-year, driven by higher adoption of preventive and specialised testing, stronger digital engagement and hyperlocal marketing initiatives. B2B revenues increased 28% year-on-year, supported by client retention, hospital outsourcing opportunities, stronger partner relationships and improved service reliability.
The company’s TruHealth portfolio grew 24% year-on-year, while the specialty portfolio increased 31% year-on-year, reflecting higher consumer preference for preventive healthcare and advanced diagnostics.
Revenue per patient (RPP) improved 11% year-on-year, while revenue per test (RPT) increased 8% year-on-year, supported by a favourable mix and higher contribution from specialised testing.
ALSO READ | Metropolis Healthcare Q2 net profit rises 13% on TruHealth, specialty portfolio growth
The company said robust demand and operational efficiencies drove margin expansion and profitability improvement. It also crossed the milestone of 5,000+ centres, strengthening accessibility and market presence across India.
The company has declared a second interim dividend of ₹1 per equity share of face value ₹2 for the financial year 2025-26. It has fixed Tuesday, May 19, 2026, as the record date for determining shareholder eligibility for the interim dividend. The dividend will be paid within 30 days of its declaration.
Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Ltd, said, "The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. At Metropolis, our focus on scientific excellence, strong doctor relationships and advanced diagnostics positions us well in this evolving healthcare landscape,” adding, “In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India.”
ALSO READ | Metropolis Healthcare targets 13-15% revenue growth in FY26 on preventive and specialty push
Shares of Metropolis Healthcare Ltd ended at ₹550, up by ₹2, or 0.36%, on the BSE today, May 13.
/images/ppid_a911dc6a-image-177886542726184122.webp)
/images/ppid_59c68470-image-177886507037891146.webp)
/images/ppid_59c68470-image-177886504809939351.webp)
